X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8620) 8620
Book Chapter (41) 41
Dissertation (27) 27
Magazine Article (18) 18
Publication (13) 13
Newspaper Article (12) 12
Conference Proceeding (6) 6
Book / eBook (3) 3
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pd-l1 (4230) 4230
immunotherapy (3683) 3683
oncology (3581) 3581
humans (3181) 3181
cancer (2756) 2756
pd-l1 protein (2695) 2695
tumors (2106) 2106
apoptosis (1832) 1832
pd-1 (1736) 1736
lymphocytes (1651) 1651
female (1549) 1549
immunology (1486) 1486
pd-1 protein (1475) 1475
immune checkpoint (1457) 1457
chemotherapy (1417) 1417
expression (1416) 1416
nivolumab (1331) 1331
lymphocytes t (1326) 1326
pd-l1 expression (1285) 1285
lung cancer (1234) 1234
male (1226) 1226
immunohistochemistry (1151) 1151
patients (1144) 1144
prognosis (1144) 1144
metastasis (1141) 1141
ligands (1123) 1123
pembrolizumab (1113) 1113
melanoma (1102) 1102
middle aged (1056) 1056
animals (1040) 1040
survival (1031) 1031
b7-h1 antigen - metabolism (1010) 1010
blockade (962) 962
aged (956) 956
cancer therapies (951) 951
metastases (901) 901
biomarkers (872) 872
cell death (852) 852
gene expression (813) 813
adult (792) 792
care and treatment (792) 792
medical prognosis (789) 789
t cells (772) 772
t-cells (770) 770
open-label (756) 756
immune system (739) 739
safety (712) 712
mutation (697) 697
antigens (695) 695
research (693) 693
therapy (693) 693
tumor-infiltrating lymphocytes (688) 688
clinical trials (687) 687
pathology (686) 686
mice (662) 662
cytotoxicity (634) 634
cell biology (630) 630
immune response (621) 621
analysis (615) 615
proteins (613) 613
carcinoma (612) 612
docetaxel (589) 589
cd8 antigen (587) 587
dendritic cells (573) 573
activation (566) 566
anti-pd-l1 antibody (564) 564
antibodies (564) 564
b7-h1 antigen - immunology (553) 553
b7-h1 antigen - genetics (549) 549
medicine, research & experimental (540) 540
review (533) 533
tumor cells (524) 524
breast cancer (514) 514
ipilimumab (509) 509
health aspects (506) 506
non-small cell lung carcinoma (501) 501
medical research (499) 499
b7-h1 antigen - antagonists & inhibitors (496) 496
aged, 80 and over (484) 484
cell line, tumor (482) 482
b7-h1 (480) 480
cell lung-cancer (465) 465
inflammation (457) 457
immunotherapy - methods (456) 456
programmed cell death 1 receptor - antagonists & inhibitors (455) 455
tumor microenvironment (450) 450
cytokines (426) 426
antibody (425) 425
genetic aspects (414) 414
neoplasms. tumors. oncology. including cancer and carcinogens (405) 405
studies (405) 405
cells (398) 398
ctla-4 (398) 398
multidisciplinary sciences (398) 398
flow cytometry (397) 397
programmed cell death 1 receptor - immunology (396) 396
antibodies, monoclonal - therapeutic use (393) 393
programmed cell death 1 receptor - metabolism (393) 393
biochemistry & molecular biology (388) 388
kinases (382) 382
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8330) 8330
Chinese (247) 247
French (68) 68
German (55) 55
Japanese (34) 34
Korean (19) 19
Russian (19) 19
Czech (3) 3
Polish (3) 3
Slovenian (2) 2
Spanish (2) 2
Turkish (2) 2
Ukrainian (2) 2
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal for immunotherapy of cancer, ISSN 2051-1426, 2018, Volume 6, Issue 1, pp. 1 - 9
Background: An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in several malignancies. However, its role with contemporary... 
PD-1/pd-L1 PD-L1 | Neutrophil-to-lymphocyte ratio | Renal cell carcinoma | Immunotherapy | Prognostic biomarker | SURVIVAL | TUMOR | IMMUNOLOGY | CANCER | FAS LIGAND EXPRESSION | ONCOLOGY | RECURRENCE | NIVOLUMAB | PD-1/pd-L1 PD-L1
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 2017, Volume 167, Issue 3, pp. 671 - 686
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 53, pp. 91779 - 91794
Journal Article
Cell (Cambridge), ISSN 0092-8674, 2018, Volume 175, Issue 2, pp. 313 - 326
Harnessing an antitumor immune response has been a fundamental strategy in cancer immunotherapy. For over a century, efforts have primarily focused on... 
PD-L1 | cancer | B7-H1 | normalization | PD-1 | immunotherapy | CELL LUNG-CANCER | METASTATIC MELANOMA | ANTI-PD-L1 ANTIBODY | B7-H1 PD-L1 | DENDRITIC CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | COMBINED NIVOLUMAB | INTERLEUKIN-2 THERAPY | DOUBLE-BLIND | MODIFIED T-CELLS | IPILIMUMAB | CELL BIOLOGY | Care and treatment | Drug therapy | Drug approval | Immunotherapy | Immunodeficiency | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Cell survival | Medical treatment | FDA approval | Health care facilities | Survival | Patients | Evidence-based medicine | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
The oncologist (Dayton, Ohio), ISSN 1549-490X, 2018, Volume 23, Issue 8, pp. 874 - 878
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for cancer. Due to the mechanism of action of ICIs, inflammatory reactions against... 
Myocarditis | Immune checkpoint inhibitor | Project Data Sphere | PD‐1/PD‐L1 inhibitor | Immune‐related adverse events | Immune-related adverse events | PD-1/PD-L1 inhibitor | MANAGEMENT | FATAL MYOCARDITIS | THERAPY | PEMBROLIZUMAB | ONCOLOGY | PD-L1 inhibitor | PATIENT | NIVOLUMAB | PD-1 | IPILIMUMAB | FULMINANT MYOCARDITIS | PD‐L1 inhibitor | Commentaries | PD‐1
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 31, pp. 51936 - 51945
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block... 
PD-L1 | B7-H1 | PD1 | PDL1 | Cancer | ACTIVATION | PROTEIN | PROGRAMMED DEATH-1 | KINASE | CBL | CELL BIOLOGY | DOWN-MODULATION | PD-L1 CO-STIMULATION | cancer | NIVOLUMAB | BLOCKADE | ANTIGEN
Journal Article
Journal Article